ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Surgical Science Sweden AB's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 1.95%.
As of today (2026-06-26), Surgical Science Sweden AB's WACC % is 11.48%. Surgical Science Sweden AB's ROC % is 1.14% (calculated using TTM income statement data).
Surgical Science Sweden AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Surgical Science Sweden AB (FRA:4P41) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Surgical Science Sweden AB's WACC % is 11.48%. Surgical Science Sweden AB's ROC % is 1.14% (calculated using TTM income statement data).
Surgical Science Sweden AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (FRA:4P41) has a ROC % of 1.95% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Surgical Science Sweden AB and its competitors.
Is Surgical Science Sweden AB's ROC % too high?
Surgical Science Sweden AB's current ROC % is 1.95%. The Healthcare Providers & Services industry median ROC % is 3.06. Surgical Science Sweden AB's value of 1.95% is 36.3% below this industry median. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's ROC % compare to VEEV and BTSG?
Surgical Science Sweden AB's ROC % of 1.95% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROC % is 3.06. Surgical Science Sweden AB's value of 1.95% is 36.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Healthcare Providers & Services company?
The median ROC % among Healthcare Providers & Services companies is 3.06, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current ROC % of 1.95% is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median ROC % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current ROC % is 1.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (FRA:4P41) is currently considered Significantly Undervalued. The stock's GF Value™ is €13.83, compared to a current price of €2.87 — trading 79.2% below its estimated fair value. The current ROC % is 1.95% and 36.3% below the Healthcare Providers & Services industry median of 3.06. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Surgical Science Sweden AB (FRA:4P41), the current ROC % is 1.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (FRA:4P41) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of €2.87 is trading 79.2% below its estimated GF Value™ of €13.83.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for FRA:4P41:
ROC %: 1.95%
GF Value™: €13.83 vs. price of €2.87 (79.2% below fair value)
Industry Position: 36.3% below the Healthcare Providers & Services median
No single metric tells the full story. See the FRA:4P41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for FRA:4P41
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4P41 has been successfully added to your 
